1259 results about "Rheumatic arteritis" patented technology

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

The invention discloses preparation and application of bionic cerium-based polyphenol nano-enzyme for treating rheumatoid arthritis, and belongs to the field of medical preparations. The method comprises the following steps: respectively complexing cerium ions and tannic acid or epicatechin gallate to prepare cerium-based polyphenol nano-enzyme, and then preparing the cerium-based polyphenol nano-enzyme wrapped by a macrophage membrane. And loading the cerium-based polyphenol nano-enzyme wrapped by the macrophage membrane into the hydrogel to prepare the hyaluronic acid-based hydrogel. The cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are characterized, it is verified that the cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are successfully synthesized, the particle size of CeTA is about 22 nm, the particle size of M-CeTA is increased to 273 nm, the particle size of CeECG is about 95 nm, and the particle size of M-CeECG is increased to 292 nm. In-vitro experiments prove that the M-CeTA and the M-CeECG do not show obvious cytotoxicity when being less than 80 mu g / mL, and have an obvious inhibition effect on expression of cell inflammatory factors on inflammatory cells.

The invention discloses a citrullinated SAA polypeptide and application thereof in preparation of a rheumatoid arthritis diagnosis product, the amino acid sequence of the citrullinated SAA polypeptide is DKYFHA-Cit-GNYDAAK-Cit-GPGGA, through the polypeptide, the citrullinated autoantigen B cell epitope of SAA and a corresponding autoantibody, namely an anti-citrullinated SAA polypeptide antibody (anti-CAP), are identified. The expression level of anti-CAP in RA patients is obviously higher than that of other disease control groups and healthy groups, and the anti-CAP has better positive rate in early RA, ESR / CRP normal RA and anti-CCP antibody / RF negative RA, and provides a new strategy for diagnosis of RA.

The invention discloses application of citrullinated endolectin-1 polypeptide in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated endolectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE, and the amino acid sequence of the citrullinated endolectin-1 polypeptide is GD- The product is used for detecting the content of the anti-citrullinated endolectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is remarkably different from that of normal healthy people and other common rheumatism immune disease patients easily confused with rheumatoid arthritis in the body of an RA patient. The kit has good sensitivity for common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnostic value for RA diagnosis.

The invention provides a composition capable of penetrating an intestinal barrier by oral administration. The composition contains a carrier or an auxiliary material of a targeted Microflod cell Dectin-1 receptor, and one or / and a plurality of medicinal components / components, wherein the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan, and the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan. The effective components / components are traditional Chinese medicine effective components / components, or / and probiotics, or / and chemical medicine components, or / and biological medicines. The invention relates to a composition capable of realizing oral administration and penetrating through an intestinal barrier, which is based on the discovery of the inventor that the composition reaches colon through gastrointestinal tracts, targets colon Microflood cells, is taken by the Microflood cells, penetrates through the intestinal barrier and enters immune tissue Colonic Patches of a colon submucosa. Based on the research, the composition disclosed by the invention can be used for treating various diseases, such as ulcerative colitis, Crohn's disease, colon cancer, rheumatoid arthritis or bacterial pneumonia after being orally taken and absorbed by rectum.

The invention discloses a bacterial polypeptide Gfo and application thereof in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the bacterial polypeptide Gfo is LNSHGFLPETE. A diagnostic product prepared from the bacterial polypeptide Gfo can effectively detect that the level of an anti-bacterial polypeptide Gfo antibody in a biological sample of a rheumatoid arthritis patient is obviously higher than that of healthy people and other rheumatoid immune diseases similar to rheumatoid arthritis. In addition, in CCP antibody and RF negative patients, the increase is still significant. Therefore, the antibacterial polypeptide Gfo antibody is an important biomarker of rheumatoid arthritis, and provides an effective new method for diagnosis of RA, especially diagnosis of serum-negative RA.

The invention relates to an active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation as well as a preparation method and application thereof. Triptolide is coupled with an active oxygen responsive group to synthesize a triptolide derivative; then, the triptolide derivative is coupled with polypeptide, and a polypeptide-reactive oxygen responsive group-triptolide conjugate is obtained; then dissolving the polypeptide-active oxygen responsive group-triptolide conjugate in a solvent, standing, and carrying out self-assembly to obtain a triptolide prodrug nanofiber solution; finally, an immunomodulator is added into the triptolide prodrug nanofiber solution for incubation, and the active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation is obtained. The hydrogel preparation disclosed by the invention can responsively release the medicine triptolide and the immunomodulator at the focus part of rheumatoid arthritis, so that the medicine accumulation of non-target organs is reduced, the safety and effectiveness of treatment are improved, and the progress of diseases is effectively controlled.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

The invention provides an organ chip unit for simulating the pathogenesis of rheumatoid arthritis, and belongs to the technical field of cell culture. The chip comprises a top-layer chip, a bottom-layer chip and a middle microporous membrane, the top-layer chip and the bottom-layer chip are separated by the middle microporous membrane, and the middle microporous membrane is used for enabling cells in a cell culture space of the top-layer chip and cells in a cell culture space of the bottom-layer chip not to be in direct contact, but interaction of signal molecules and substance exchange can be carried out; synovial cells and cartilage cells are injected into the bottom-layer chip or the top-layer chip to be cultured. According to the invention, multi-cell three-dimensional co-culture can be realized. Through the additional stress stimulation co-culture part, the influence of pressure or tension on the cell environment can be judged, and the actual condition that rheumatoid arthritis joints receive pressure or tension for a long time can be simulated. The synovial cells and the cartilage cells are used, so that the structure of the inflammation joint in a living body can be truly reflected, and the interaction among various cell tissues can be reflected.

The invention discloses a rheumatoid arthritis diagnosis product and system and application thereof, and relates to the technical field of rheumatoid arthritis. The diagnostic marker comprises calcium, a ratio of arginine to ornithine, a ratio of phenylalanine to tyrosine, an anti-cyclic citrullinated peptide antibody and lysine. The invention provides a biomarker capable of accurately diagnosing rheumatoid arthritis RA, which comprises five indexes, namely calcium, the proportion of arginine to ornithine, the proportion of phenylalanine to tyrosine, an anti-cyclic citrullinated peptide antibody (anti-CCP) and lysine. The five indexes have the technical advantages of few indexes and excellent diagnosis performance. A diagnosis model constructed based on the five indexes has good sensitivity, specificity and accuracy. The kit can be used for diagnosis of rheumatoid arthritis.

The invention relates to the field of application of medicines for treating rheumatoid arthritis, and discloses an application method of targeted MTHFD2 in preparation of medicines for treating bone destruction of rheumatoid arthritis, (1) the level of MTHFD2 in knee joints of rheumatoid arthritis patients and mice is increased; (2) the expression of MTHFD2 is up-regulated in the process of differentiating osteoclast precursor cells from mice and humans into osteoclasts; (3) the MTHFD2 inhibitor can significantly inhibit differentiation of osteoclasts from mice and humans; (4) MTHFD2 gene silencing can inhibit differentiation of mouse-derived osteoclasts, MTHFD2 gene overexpression can promote differentiation of osteoclasts, and reliability of MTHFD2 as a therapeutic target is verified; and (5) the MTHFD2 inhibitor can improve the bone destruction of arthritis mice and increase the bone tissue density, which prompts that the targeted MTHFD2 is useful for the treatment or prevention of rheumatoid arthritis and other diseases.

The invention relates to the technical field of digital health, in particular to a personalized rehabilitation exercise method for rheumatoid arthritis patients based on a BCW theory, which comprises the following steps: acquiring joint angle change and calculating a pain delay response coefficient, detecting fluctuation of supporting force and stabilizing force to obtain a joint load tolerance value, analyzing respiratory coordination to generate a respiratory coordination index, and performing rehabilitation training on the respiratory coordination index. The method comprises the steps that a joint angle sensor and pain intensity data are analyzed, a BCW capacity factor weight value is generated in a weighted mode, a fuzzy control algorithm is input to conduct hierarchical mapping adjustment on action amplitude frequency and rest intervals, and exercise adaptability feedback data are generated through monitoring completion degree and pain feedback. The exercise intensity is dynamically adjusted in real time through a data model, a personalized rehabilitation scheme is automatically optimized, the problems that subjective feedback is relied on, and physiological changes cannot be responded in time are solved, more accurate exercise amount adjustment is provided, the situation that the joint burden is increased due to improper exercise intensity is avoided, and the rehabilitation process is effectively promoted.

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

The invention provides an auxiliary system for a rheumatoid arthritis medication scheme. The auxiliary system is used for matching similar historical medication schemes, related medication costs and treatment results used for treating historical rheumatoid arthritis patients and judging whether transaminase abnormity occurs or not based on the treatment conditions of current patients, analyzing each historical medication scheme, and determining whether the transaminase abnormity occurs or not according to the analyzed historical medication schemes and the analyzed transaminase abnormity. And obtaining scores or grades of three dimensions of safety, effectiveness and economy of each historical medication scheme. And based on the requirements or tendencies of the patient on the medication schemes in three dimensions of safety, effectiveness and economy, screening out corresponding candidate medication schemes from the historical medication schemes and recommending the candidate medication schemes. According to the technical scheme, by means of the computer technology, the corresponding medication scheme is automatically recommended based on the medication tendency of the rheumatoid arthritis patient, decision assistance is provided, the time for adapting the medication scheme for the patient is saved, and the satisfaction degree of the rheumatoid arthritis patient to the medication scheme is improved.

The invention discloses a risk assessment method for rheumatoid arthritis accompanied with cognitive impairment based on big data, and belongs to the field of data feature extraction, and the method specifically comprises the steps: carrying out the unified calling of collected clinical, laboratory and iconography features as an original feature set, and completing the preprocessing through multiple interpolation and Z-score standardization; inputting the original feature set into a self-attention network, and generating interaction feature representation for mining high-order interaction; low-dimensional potential feature vectors are compressed, and combined training is carried out through reconstruction and discriminant loss; inputting the potential feature vectors into an XGBoost model, and screening out a preliminary candidate feature subset; performing global and local importance evaluation on the candidate feature subsets by adopting SHAP, and iteratively rejecting features of which the contribution degrees are lower than a threshold value epsilon until the final feature subset is stable; and respectively inputting the final feature subsets into the simplified ResNet and LightGBM to obtain two groups of risk scores, and then generating a fusion risk score through weighted fusion.

The invention provides a rheumatoid arthritis patient low muscle quality risk prediction method based on an uncertainty perception stacked meta-learning structure, and belongs to the technical field of machine learning. The method comprises the following steps: acquiring a rheumatoid arthritis data set; constructing a base learner set comprising a table Transform class network and a gradient boosting tree class model; splicing the out-of-fold prediction probabilities of all the base learners and the statistics thereof to form a meta-feature matrix; taking the meta feature matrix as input, and constructing and training a meta learner comprising a spectrum normalization multilayer perceptron and a random feature Gaussian process output layer; collecting to-be-detected data, inputting the to-be-detected data into the trained base learner set and the trained meta learner in sequence, and performing temperature scaling and beta-calibration on a prediction result; and taking the calibrated prediction probability as a final prediction result. Through multi-source data fusion, the defects of an existing model in the aspects of practicability, probability reliability and the like are overcome.

The present invention relates to a composition comprising, separately or together, methotrexate (MTX) and (E)-N-trans-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium acetate (AP1189), or pharmaceutically acceptable derivatives thereof, for use in a method of treating an arthritis disease, such as rheumatoid arthritis.

The invention discloses a method for predicting periprosthetic infection of an artificial joint after a rheumatoid arthritis operation, and belongs to the technical field of medical treatment, the method can be applied to risk prediction of periprosthetic infection (PJI) of the artificial joint after the rheumatoid arthritis operation, and the method comprises the following steps: carrying out feature selection through a Boruta algorithm; an integrated machine learning algorithm is developed based on a genetic algorithm and an SMOTEENN algorithm in combination with machine learning for risk prediction, so that the accuracy and practicability of PJI risk prediction after joint replacement of a rheumatoid arthritis patient are improved. According to the rheumatoid arthritis artificial joint postoperative periprosthetic infection risk prediction method, a more accurate prediction and personalized treatment scheme can be provided for a doctor, and preoperative management of joint replacement of a rheumatoid arthritis patient is optimized, so that PJI is prevented to the greatest extent, and the joint function and life quality of the patient are improved.

The present application belongs to the technical field of medicine, and particularly relates to the use of tetrahydrojatrorrhizine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating rheumatoid arthritis. Experimental results show that tetrahydrojatrorrhizine can effectively alleviate the foot swelling level of CIA rats, reduce the arthritis score, and inhibit the progression of rheumatoid arthritis. Blood routine analysis shows that the administration of tetrahydrojatrorrhizine reduces the number of immune cells in the blood and weakens the immune level of the body. In addition, the experimental results also show that tetrahydrojatrorrhizine can inhibit synovial hyperplasia and relieve joint damage. Therefore, tetrahydrojatrorrhizine has the prospect of being developed into an oral medicament for treating rheumatoid arthritis, provides more treatment options for clinically treating rheumatoid arthritis, and has important social and economic values.

The present invention relates methods of producing B cell depletion in autoimmune diseases. More specifically, the invention shows the use of CD-19 bispecific targeting molecules to effectively treat autoimmune disorders such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjögren's disease (SjD).

A preparation method for a micro-vehicle formed by enveloping siRNA-loaded polypeptide dendrimer nanogel with a cell membrane of engineered MSCs, and the use of same. The method comprises: using lentivirus-mediated gene transfection technology for constructing MSCs that highly express CXCR4 and PSGL-1; using cytokinin B for stimulating a cell to generate vesicles, and then performing centrifugation to collect the vesicles; by means of the electrostatic attraction between polypeptide dendrimer nanoparticles and siRNAs, attaching the siRNAs of IL-6 and HIF-1α into the polypeptide dendrimer nanoparticles; and by means of using a membrane extruder, enveloping the siRNA-loaded polypeptide dendrimer nanogel with the cell membrane. The prepared micro-vehicle exhibits a good property of aggregating at inflammatory blood vessel sites and a targeting function for joint cavities with rheumatoid arthritis. In addition, the loaded siRNAs can inhibit the expressions of IL-6 and HIF-1α in the joint cavities and inhibit the cell migration and angiogenesis. The micro-vehicle targeting inflammation sites has the advantages of excellent biocompatibility, ideal siRNA loading ratio, good inflammation targeting function, etc.

The present disclosure relates to the use of an anti-IL6 receptor antibody for treating unacceptable pain in subjects with rheumatoid arthritis. Subjects with unacceptable pain can have, e.g., refractory pain or strict refractory pain.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention discloses a prediction model construction method for rheumatoid arthritis accompanied with brain cognitive impairment, and belongs to the technical field of medical assistance, and the method specifically comprises the steps: synchronously collecting multi-source dynamic behavior data when a patient executes standardized joint activity training each time; vector superposition comparison under a three-dimensional coordinate system is carried out on the joint motion trajectory data, and the trajectory offset degree of each motion phase point is calculated; fractal dimension calculation is carried out on the moving path topological structure data, and path complexity is quantized; performing feature matrix construction on the facial micro-expression data, and calculating covariance structure change of an expression parameter matrix; and performing time domain alignment and causal analysis on the spatio-temporal trajectory offset event, the path topology degradation characteristic and the expression parameter variation signal, and when the three types of abnormalities present time coupling in two continuous training periods and meet a preset condition, generating early warning of cognitive impairment.

The invention discloses a rheumatoid arthritis foot orthopedic and warm-keeping device, and relates to the technical field of arthritis foot orthopedic, the rheumatoid arthritis foot orthopedic and warm-keeping device comprises a bottom plate, the bottom plate is fixedly connected with a shell, one side of the bottom of the shell is rotatably connected with an insertion rod, one end of the insertion rod is fixedly connected with a turnover plate, the upper surface of the turnover plate is provided with two connecting blocks, and the two connecting blocks are fixedly connected with the bottom of the shell. And the upper surface of the other end of the bottom plate is fixedly connected with a front plate. According to the rheumatoid arthritis foot orthopedic and warm-keeping device, in the process that a patient lifts the instep upwards for the first time, a limiting rod slides into a short groove from a long groove, a sliding rod extrudes a force storage spring to enable the force storage spring to form downward thrust, the downward thrust formed by extruding the force storage spring by the sliding rod is larger, and therefore the foot orthopedic effect is improved. When the patient lifts the instep upwards for the second time, the downward thrust of the force storage spring helps the patient to lift the instep, the burden of instep muscles of the patient is relieved through the stored force of the force storage spring, and the effect of protecting the joints of the patient is achieved.

Provided herein are compositions and methods for the treatment of an autoimmune or inflammatory disease, such as rheumatoid arthritis. Said compositions comprise a TNFR1 inhibitor. Some embodiments comprise combination therapy featuring the TNFR1 inhibitor with at least one additional anti-inflammatory therapeutic agent.

The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, and methods of treatment, including treatment of rheumatoid arthritis and juvenile idiopathic arthritis using the same. The treatment methods generally comprise administering to a patient (e.g., a pediatric patient) a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.

The present disclosure provides methods of treating rheumatoid arthritis comprising administering a MNK inhibitor.

The invention belongs to the technical field of food and medicine, and relates to application of corn germ concentrated powder in improvement of osteoarthritis. The invention particularly relates to application of corn germ concentrated powder, namely corn antioxidant multienzyme, in preparation of medicines or health-care foods for treating rheumatoid arthritis and osteoporosis. In the corn germ concentrated powder, superoxide dismutase / (U / g) is greater than or equal to 8500, glutathione peroxidase / (U / g) is greater than or equal to 5000, and catalase / (U / g) is greater than or equal to 750. The corn germ concentrated powder can also be prepared by the following method: cleaning corn, germinating, adding water into the germinated corn, grinding and pulping, adding a settling agent into the corn steep liquor, standing, taking supernate, adding part of sodium ascorbate, performing temperature-controlled concentration, adding the rest sodium ascorbate and a stabilizer into the concentrated solution, and uniformly mixing to obtain the corn germ concentrated powder. And drying at controlled temperature, crushing, and mixing with a proper amount of silicon dioxide. The prepared corn germ concentrated powder has the effect of resisting rheumatoid arthritis.

The invention relates to a mesenchymal stem cell immunomodulatory function enhancing technology based on gene editing. The invention relates to the field of biomedical engineering and regenerative medicine, and particularly provides a method for enhancing the immune regulation function of mesenchymal stem cells through a CRISPR-Cas9 gene editing technology, and aims at up-regulating IDO1, IL-10 and other key genes in a targeted manner and remarkably improving the excessive immune response inhibition capability of MSCs. The technology can be used for developing high-efficiency and low-toxicity novel cell drugs for treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.